MY008211A not checked
Wuhan Createrna Science and Technology Co., Ltd
FollowEvery change as it happens, and a Monday email
Trials
5 active
11 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “MY008211A tablets Participants will receive MY008211A at a dose of 400 mg orally b.i.d”In the company’s words, NCT06932471 on ClinicalTrials.gov
- Tested for
- Paroxysmal Nocturnal Hemoglobinuria (PNH) (2 trials), Paroxysmal Nocturnal Hemoglobinuria, Paroxysmal Nocturnal Haemoglobinuria (PNH), IgA Nephropathy (IgAN)
- Main trialPhase 3
- “The main purpose of this study is to evaluate the efficacy of MY008211A in PNH patients with residual anemia despite treatment with anti-C5 antibody.”In the company’s words, NCT06932471 on ClinicalTrials.gov
- Other names
- no other name · no name
Other drugs for Paroxysmal Nocturnal Hemoglobinuria (PNH)
- NTQ5082Nanjing Chia-tai Tianqing Pharmaceutical · Phase 3
- CrovalimabRoche · Phase 3
- DanicopanAlexion Pharmaceuticals, Inc. · Phase 3
- VSA012Bisirna Therapeutics (Suzhou) Co., Ltd. · Phase 3
- IptacopanNovartis Pharmaceuticals · Phase 3
- FXS6837Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. · Phase 3
Coming up2
- 30 DecPhase 2/3 trial completes · ClinicalTrials.gov
- Jul 2027Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials11
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | 30 Dec 2025 | Study of Safety and Efficacy of MY008211A in Patients With Residual Anemia Despite Anti-C5 Antibody Treatment | |
| Phase 3Recruiting | 30 Dec 2025 | Study of Safety and Efficacy of MY008211A in Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Who Are Naive to Complement Inhibitor Therapy | |
| Phase 2/3Recruiting | 30 Dec 2026 | Long-term Safety and Tolerability of MY008211A Tablets in Patients With Paroxysmal Nocturnal Hemoglobinuria | |
| Phase 2Not yet recruiting | 15 Jun 2026 | Study to Evaluate the Efficacy and Safety of MY008211A in Subjects with Primary Immunoglobulin a Nephropathy (IgAN) | |
| Phase 2Not yet recruiting | Jul 2027 | Study of Safety and Efficacy of MY008211A in in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) | |
| Phase 2Completed | 30 Apr 2024 | A Study of MY008211A in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) | |
| Phase 1Completed | 23 Oct 2022 | Effect of Food on Pharmacokinetics of MY008211A Tablets in Healthy Adult Subjects | |
| Phase 1Completed | 4 Jun 2023 | A Study of Single-dose MY008211A in Healthy Adults | |
| Phase 1Completed | 30 Jun 2023 | A Study of Multiple Ascending Doses MY008211A in Healthy Adults | |
| Phase 1Unknown | 27 Sep 2024 | To Evaluate the Effect of Single Oral Dose of MY008211A Tablets on QTc Interval in Healthy Subjects | |
| Phase 1Completed | 28 Dec 2024 | A Pharmacokinetic and Safety Study of MY008211A Tablets in Subjects With Impaired or Normal Hepatic Function |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026